Original article| Volume 45, 102400, October 2020

Promising recovery biomarkers after first event acute demyelinating optic neuritis


      • LCVA (2.5%) rather than HCVA is more sensitive marker of visual function recovery
      • LCVA (2.5%), 10-2 threshold perimetry and GCL thickness and thinning are potential recovery biomarkers after first event of acute demyelinating optic neuritis.
      • The 10-2 threshold perimetry as a novel strategy in demyelinating optic neuritis research better characterizes the outcome visual deficits.



      Acute demyelinating optic neuritis is often a first episode of subsequent CNS demyelinating disease, most frequently multiple sclerosis (MS). The majority of the patients have substantial recovery of the high contrast visual acuity (HCVA) and 30-2 perimetry, but reduced contrast sensitivity persists in 56% of eyes after an episode of optic neuritis. Cross sectional studies of MS patients show low contrast visual acuity (LCVA) correlates modestly with RNFL thickness and macula ganglion cell +IPL layer (GCL) thickness. Considering the potential severity of the vision deficits at onset, and GCL thinning at outcome, we hypothesized 10-2 perimetry and LCVA deficits would be frequent following an episode of optic neuritis.


      We prospectively studied 32 eyes of 32 patients (9 men, 23 women, age 34 years ± 10) with first time acute optic neuritis. We measured LCVA 2.5% (# letters seen), GCL thickness and loss, and 10-2 mean deviation (MD in decibels, dB) within 15 days from symptoms onset and at six months. The 10-2 threshold perimetry, a novel assessment in the MS research field, included to further characterize central vision function. We used correlation analysis to assess associations between GCL thickness and thinning and 10-2 perimetry as well as LCVA 2.5% at six months.


      Compared to fellow eyes we found significant residual LCVA deficits in 28/32 study eyes at 6 months with 12.6 ± 15.8 letters seen, p=0.001). Similarly, 10-2 MD threshold perimetry in the study eyes at 6 months showed significant difference relative to the fellow eyes, p=0.01.
      In regards to GCL changes at 6 months, we found statistically significant reduction of the GCL thickness in the study eyes relative to the fellow eyes (study eyes 69.6 ± 9.6 µm, fellow eyes 82.7 ± 4.7 µm, p=0.001), with thinning present in 29/32 eyes. The mean GCL thinning at 6 months in the study eyes was 12.4 ± 8.4 µm.
      Correlation analysis of associations between primary outcome measures at 6 months showed significant relationship between GCL thickness and 10-2 MD threshold perimetry (0.43, p = 0.015) but not with LCVA. At six months, the mean GCL thinning strongly correlated with the 10-2 MD (-0.60, p=0.01) and moderately with LCVA (-0.46, p=0.008).


      GCL thickness is the best structural and LCVA and 10-2 MD are sensitive functional measures for determining residual deficits due to optic neuritis.  The 10-2 MD correlates best with the outcome GCL thickness and loss. Our findings also suggest that 10-2 threshold perimetry and macular GCL can provide functional and structural promising biomarker signals to explore neuro-protective research.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Multiple Sclerosis and Related Disorders
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Aggarwal D.
        • et al.
        Patterns of ganglion cell complex and nerve fiber layer loss in nonarteritic ischemic optic neuropathy by Fourier-domain optical coherence tomography.
        Invest. Ophthalmol. Vis. Sci. 2012; 53: 4539-4545
        • Andorra M.
        • et al.
        Using acute optic neuritis trials to assess neuroprotective and remyelinating therapies in multiple sclerosis.
        JAMA Neurol. 2019;
        • Balcer L.J.
        • et al.
        Natalizumab reduces visual loss in patients with relapsing multiple sclerosis.
        Neurology. 2007; 68: 1299-1304
        • Balcer L.J.
        • et al.
        Alemtuzumab improves visual outcomes in treatment-naïve patients with relapsing–/INS;remitting multiple sclerosis (RRMS): analysis from the phase 3 care-ms I study.
        J. Neurol. Sci. 2013; 333: e375
        • Balcer L.J.
        • et al.
        Validity of low-contrast letter acuity as a visual performance outcome measure for multiple sclerosis.
        Mult. Scler. 2017; 23: 734-747
        • Beck R.W.
        • et al.
        A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. the optic neuritis study group.
        N. Engl. J. Med. 1992; 326: 581-588
        • Chahin S.
        • et al.
        Vision in a phase 3 trial of natalizumab for multiple sclerosis: relation to disability and quality of life.
        J. Neuroophthalmol. 2015; 35: 6-11
        • De Moraes C.G.
        • et al.
        Association of macular visual field measurements with glaucoma staging systems.
        JAMA Ophthalmol. 2019; 137: 139-145
        • Green A.J.
        • et al.
        Ocular pathology in multiple sclerosis: retinal atrophy and inflammation irrespective of disease duration.
        Brain. 2010; 133: 1591-1601
        • Ikuta F.
        • Zimmerman H.M.
        Distribution of plaques in seventy autopsy cases of multiple sclerosis in the United States.
        Neurology. 1976; 26: 26-28
        • Keltner J.L.
        • et al.
        Visual field profile of optic neuritis: a final follow-up report from the optic neuritis treatment trial from baseline through 15 years.
        Arch. Ophthalmol. 2010; 128: 330-337
        • Kupersmith M.J.
        • et al.
        Scanning laser polarimetry reveals status of RNFL integrity in eyes with optic nerve head swelling by OCT.
        Invest. Ophthalmol. Vis. Sci. 2012; 53: 1962-1970
        • Kupersmith M.J.
        • et al.
        Retinal ganglion cell layer thinning within one month of presentation for optic neuritis.
        Mult. Scler. 2016; 22: 641-648
        • Miller D.H.
        • Chard D.T.
        • Ciccarelli O.
        Clinically isolated syndromes.
        Lancet Neurol. 2012; 11: 157-169
        • Nolan R.C.
        • et al.
        Evolution of visual outcomes in clinical trials for multiple sclerosis disease-modifying therapies.
        J. Neuroophthalmol. 2018; 38: 202-209
        • Polman C.H.
        • et al.
        Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria.
        Ann. Neurol. 2011; 69: 292-302
        • Raza A.S.
        • et al.
        Retinal ganglion cell layer thickness and local visual field sensitivity in glaucoma.
        Arch. Ophthalmol. 2011; 129: 1529-1536
        • Saidha S.
        • et al.
        Visual dysfunction in multiple sclerosis correlates better with optical coherence tomography derived estimates of macular ganglion cell layer thickness than peripapillary retinal nerve fiber layer thickness.
        Mult. Scler. 2011; 17: 1449-1463
        • Seigo M.A.
        • et al.
        In vivo assessment of retinal neuronal layers in multiple sclerosis with manual and automated optical coherence tomography segmentation techniques.
        J. Neurol. 2012; 259: 2119-2130
        • Silbermann E.
        • Wooliscroft L.
        • Bourdette D.
        Using the anterior visual system to assess neuroprotection and remyelination in multiple sclerosis trials.
        Curr. Neurol. Neurosci. Rep. 2018; 18: 49
        • Trobe J.D.
        • et al.
        Contrast sensitivity and other vision tests in the optic neuritis treatment trial.
        Am. J. Ophthalmol. 1996; 121: 547-553
        • Walter S.D.
        • et al.
        Ganglion cell loss in relation to visual disability in multiple sclerosis.
        Ophthalmology. 2012; 119: 1250-1257
        • Wingerchuk D.M.
        • et al.
        Revised diagnostic criteria for neuromyelitis optica.
        Neurology. 2006; 66: 1485-1489